Essential Fatty Acid Deficiency clinical trials at UCLA

1 research study open to eligible people

Occurrence of EFAD in Pediatric Patients with PNAC Who Require More Than Eight Weeks of Omegaven Treatment
open to eligible people ages up to 17 years
This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population
Los Angeles, California and other locations

Our lead scientists for Essential Fatty Acid Deficiency research studies include Kara L. Calkins, MD.

Last updated: February 26, 2025

Occurrence of EFAD in Pediatric Patients with PNAC Who Require More Than Eight Weeks of Omegaven Treatment